Jazz Pharmaceuticals (JAZZ) Tops Q4 EPS by 62c; Guides Above Views

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of $3.64, $0.62 better than the analyst estimate of $3.02. Revenue for the quarter came in at $476.5 million versus the consensus estimate of $459.72 million.

GUIDANCE:

Jazz Pharmaceuticals sees FY2019 EPS of $14.30-$15.00, versus the consensus of $13.98. Jazz Pharmaceuticals sees FY2019 revenue of $2.05-2.13 billion, versus the consensus of $2.03 billion.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.

You May Also Be Interested In

• Goldman Sachs Assumes Jazz Pharmaceuticals (JAZZ) at Buy
• Darden Restaurants falls as Q1 revenue misses expectations
• MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance